Clinical Trial Update: Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial evaluating Toca 511/Toca FC added to standard therapy for newly diagnosed glioblastoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Glioblastoma
• Oligodendroglioma

Drugs mentioned

• Toca 511 (retroviral replicating vector expressing cytosine deaminase)
• Toca FC (5-fluorocytosine)

Snippet

Sponsor: NRG Oncology | Conditions: Anaplastic Astrocytoma, Glioblastoma | Phase 2, Phase 3 | Status: WITHDRAWN